SUNY Downstate Medical Center is one of 90 sites participating in the first U.S. clinical trial (Symplicity HTN-3) evaluating the safety and effectiveness of renal denervation in the management of treatment-resistant hypertension. The project is a collaboration between the Department of Medicine and the Department of (Interventional) Radiology.
Renal denervation is approved for treatment-resistant hypertension in several countries outside of the U.S., where several thousand patients have benefited from this new treatment. In the U.S., this clinical trial is being conducted to produce the data required for approval by the FDA.
People considering participation in the trial must have hypertension (≥ 160 mm Hg) and be unable to control their high blood pressure even when taking three or more blood pressure medications. Pregnant women and patients who have type I diabetes are not eligible.
For more information, please call us at (718) 270-2107.
Jacek Preibisz, MD
Dr. Preibisz's schooling and training were at the Medical Academy, Warsaw, in his native Poland, where he rose to the position of Professor of Medicine in the Cardiovascular and Hypertension Department. At that institution, he also became Head of the Medical Intensive Care Unit and Coronary Care Unit, and Director of the Pulmonary and Cardiac Glycosides Laboratories.
During his tenure at the Medical Academy, Dr. Preibisz spent a year in the US as a special WHO research fellow in cardiology at Columbia. In 1978-1980, he was chief cardiology consultant for Western Algeria. In 1980, he immigrated permanently to the US and joined the faculty of John Laragh's Hypertension Center at Cornell as Assistant Professor of Medicine; he was promoted to the rank of Associate Research Professor of Medicine 5 years later. At the Hypertension Research Laboratories, Dr. Preibisz developed a method for measuring arginine vasopressin, a key step in the development of vasopressin therapy that is now routinely employed in several clinical situations; he received NIH funding for these studies. His other work involved elucidation of the role of the renin-angiotensin system in hypertension, assessment of the renin-angiotensin system in heart failure, and definition of the role of calcium metabolism in blood pressure control management.
After 8 years at Cornell, Dr. Preibisz left the full-time faculty to become Associate Director of Cardiovascular Clinical Research for Hoffmann-LaRoche, Inc., where he worked for 8 years in drug development and formulation of clinical trials. Returning to Cornell in 1996, shortly after John Laragh's retirement and the restructuring of the Hypertension Center, Dr. Preibisz altered his activity to include research, clinical teaching and clinical coverage in the Department of Medicine, and private practice of cardiology at New York-Presbyterian Hospital. In 2004, he expanded his activities and joined the Division of Cardiovascular Pathophysiology for greater involvement in research, and became a key member of the team researching the epidemiology of heart valve diseases. Though he continued his private practice, his responsibilities in the division also included clinical care, at which he was outstanding. The first major research project with which he was associated in Cardiovascular Pathophysiology was a unique assessment of the prognostic importance of hypertension in aortic regurgitation, and the impact of impedance-lowering drug therapy in this disease, published in 2005. Indeed, despite his absence from full-time academic activities for several years, Dr. Preibisz has published 63 journal articles and chapters. He is also a regular reviewer for several major peer-reviewed cardiovascular journals.
In 2009, Dr. Preibisz was offered the position of Professor of Medicine at SUNY Downstate's Division of Cardiovascular Medicine and also became Director of the Preventive Cardiology and Hypertension Program. Dr. Preibisz, a certified specialist in hypertension, is Principal Investigator in Medtronic's Symplicity HTN-3 trial, dedicated to evaluation of the renal denervation procedure in patients with severe, resistant hypertension, as well as Co-Investigator in a hypertensive drug study sponsored by Forest Pharmaceuticals.
Nathaniel Winer, MD
Dr. Winer is a graduate of Harvard College and New York University School of Medicine. He did his internship in Medicine at Bellevue Hospital, his residency in Internal Medicine at the Manhattan campus of the Veterans Affairs New York Harbor Healthcare System, and Fellowships in Endocrinology at Washington University School of Medicine in St. Louis and the University of Missouri School of Medicine in Columbia, Missouri. He was Chief of Medicine at Menorah Medical Center in Kansas City before joining the University of Missouri-Kansas City School of Medicine where he was Professor of Medicine and Chief of Endocrinology.
Dr. Winer has researched the physiology of the renin-angiotensin-aldosterone system in experimental animals and in humans, focusing on the role of the sympathetic nervous system in regulating renin secretion. He has conducted more than 100 clinical trials on a range of antihypertensive agents. Recently, he has studied vascular compliance (blood vessel stiffness) and endothelial dysfunction (abnormal action of the cells of the inner surface of blood vessels) in patients with high blood pressure and diabetes. For the past 10 years he has participated in training Endocrine fellows at SUNY Downstate Medical Center, and is Director of the Endocrine and Thyroid Clinics at Kings County Hospital Center. Dr. Winer is a Fellow and a Clinical Specialist of the American Society of Hypertension.